Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AsfiledCriticalH Lundbeck As
Publication of MY166773ApublicationCriticalpatent/MY166773A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
The present invention relates to deuterated 1-piperazino-3-phenyl-indanes and salts thereof with activity at dopamine receptors D1 and D2 as well as the 5HT2 receptors in the central nervous system, to medicaments comprising such compounds as active ingredients, to the use of such compounds in the treatment of diseases in the central nervous system, and to methods of treatment comprising administration of such compounds. (Fig. 1)
MYPI2013004503A2011-06-202012-06-19Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia
MY166773A
(en)
Method of administration of 4-((1r,3s)-6-chloro-3-phenyl-indan-1- yl)-1,2,2-trimethyl-piperazine and the salts thereof in the treatment of schizophrenia.
Method to treat a human patient with multiple sclerosis with laquinimod, at a daily dose of about 1.2mg; an oral unit dosage form of 1.2 mg of laquinimod and a carrier